215.75
price up icon1.43%   3.04
after-market アフターアワーズ: 215.75
loading
前日終値:
$212.71
開ける:
$210
24時間の取引高:
1.45M
Relative Volume:
1.65
時価総額:
$10.39B
収益:
$4.03B
当期純損益:
$-182.84M
株価収益率:
-57.38
EPS:
-3.7603
ネットキャッシュフロー:
$391.29M
1週間 パフォーマンス:
+16.62%
1か月 パフォーマンス:
+37.66%
6か月 パフォーマンス:
+5.94%
1年 パフォーマンス:
+42.32%
1日の値動き範囲:
Value
$210.00
$217.19
1週間の範囲:
Value
$178.92
$217.19
52週間の値動き範囲:
Value
$144.26
$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1096)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
19,700
Name
Twitter
@criverlabs
Name
次回の収益日
2026-08-05
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, NTRA

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CRL icon
CRL
Charles River Laboratories International Inc
215.75 10.25B 4.03B -182.84M 391.29M -3.7603
TMO icon
TMO
Thermo Fisher Scientific Inc
513.03 187.95B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
196.19 136.75B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
551.50 43.78B 4.45B 1.10B 1.06B 13.59
A icon
A
Agilent Technologies Inc
136.01 38.27B 7.23B 1.41B 1.09B 4.979
NTRA icon
NTRA
Natera Inc
261.91 37.34B 2.50B -226.32M 71.51M -1.6412

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-06-17 アップグレード Morgan Stanley Equal-Weight → Overweight
2026-05-29 アップグレード CLSA Hold → Outperform
2026-04-14 開始されました RBC Capital Mkts Outperform
2025-12-15 アップグレード BofA Securities Neutral → Buy
2025-11-17 アップグレード Argus Hold → Buy
2025-11-06 アップグレード Robert W. Baird Neutral → Outperform
2025-10-06 アップグレード William Blair Mkt Perform → Outperform
2025-10-02 アップグレード Barclays Equal Weight → Overweight
2025-09-09 アップグレード Jefferies Hold → Buy
2025-07-09 アップグレード Citigroup Neutral → Buy
2025-05-23 アップグレード Redburn Atlantic Neutral → Buy
2025-05-14 アップグレード TD Cowen Hold → Buy
2025-05-08 アップグレード Evercore ISI In-line → Outperform
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
07:33 AM

Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus - Ad-hoc-news.de

07:33 AM
pulisher
06:26 AM

Enterprise value to revenue forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView

06:26 AM
pulisher
02:48 AM

Enterprise value to revenue forward of Charles River Laboratories International, Inc. – DUS:RV6 - TradingView

02:48 AM
pulisher
Jun 26, 2026

Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBIT forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 26, 2026
pulisher
Jun 26, 2026

RV6 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Charles River Laboratories International Inc (CRL)'s Uncertain F - GuruFocus

Jun 26, 2026
pulisher
Jun 26, 2026

Is Charles River (CRL) Quietly Redefining Its Moat Through Lilly’s AI-Driven TuneLab Collaboration? - Yahoo Finance

Jun 26, 2026
pulisher
Jun 26, 2026

How is Charles River Laboratories’ stock performance compared to other health care stocks? - MSN

Jun 26, 2026
pulisher
Jun 26, 2026

Charles River Laboratories analyst calls stay supportive, shares with a clear Wall Street consensus - Ad-hoc-news.de

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Price to sales forward of Charles River Laboratories International, Inc. – MUN:RV6 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Charles River Laboratories International Inc (CRL) Stock Up 5.2% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Charles River Laboratories International, Inc. Actuals & Estimates (NYSE:CRL) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Charles River Laboratories lands Morgan Stanley upgrade, shares in S&P 500 medtech spotlight - Ad-hoc-news.de

Jun 25, 2026
pulisher
Jun 25, 2026

Charles River Labs, Thursday chart focus keeps shares under review - Ad-hoc-news.de

Jun 25, 2026
pulisher
Jun 25, 2026

CRL Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat? - simplywall.st

Jun 25, 2026
pulisher
Jun 24, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Jun 24, 2026
pulisher
Jun 24, 2026

Charles River Laboratories International Jumps 8.1% in Broad Rally - AlphaStreet

Jun 24, 2026
pulisher
Jun 24, 2026

Charles River upgraded, IQVIA downgraded as Morgan Stanley revisits CRO coverage - MSN

Jun 24, 2026
pulisher
Jun 23, 2026

2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500

Jun 23, 2026
pulisher
Jun 23, 2026

Charles River Laboratories consensus in focus, shares under Wall Street scrutiny - Ad-hoc-news.de

Jun 23, 2026
pulisher
Jun 23, 2026

Charles River Laboratories International Inc - TradingKey

Jun 23, 2026
pulisher
Jun 22, 2026

Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance

Jun 22, 2026
pulisher
Jun 22, 2026

Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch

Jun 22, 2026
pulisher
Jun 22, 2026

Charles River Laboratories consensus in focus, shares tracked ahead of next earnings - Ad-hoc-news.de

Jun 22, 2026
pulisher
Jun 22, 2026

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks? - Yahoo Finance

Jun 22, 2026
pulisher
Jun 22, 2026

Charles River Laboratories Inte (CRL): Investor Outlook Reveals 16.4% Potential Upside Amidst Robust Buy Ratings - DirectorsTalk Interviews

Jun 22, 2026
pulisher
Jun 21, 2026

Charles River Labs StockMorgan Stanley upgrade highlights biopharma tailwind - AD HOC NEWS

Jun 21, 2026
pulisher
Jun 21, 2026

Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade - simplywall.st

Jun 21, 2026
pulisher
Jun 19, 2026

Why Charles River Labs’ Luminex immunoassay service matters for biotech teams - AD HOC NEWS

Jun 19, 2026
pulisher
Jun 19, 2026

Charles River collaborates with Lilly TuneLab platform - Yahoo Finance

Jun 19, 2026
pulisher
Jun 19, 2026

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise - BioSpace

Jun 19, 2026
pulisher
Jun 18, 2026

CRL News | CHARLES RIVER LABORATORIES (NYSE:CRL) - ChartMill

Jun 18, 2026
pulisher
Jun 18, 2026

Global Cell and Gene Therapy CDMO Market Anticipating Remarkable Growth at a CAGR of ~24% by 2034 | DelveInsight - GlobeNewswire Inc.

Jun 18, 2026
pulisher
Jun 18, 2026

Why Charles River Labs leans on the Microbial Solutions Celsis platform for faster QC - AD HOC NEWS

Jun 18, 2026
pulisher
Jun 18, 2026

Charles River Laboratories International Inc (CRL) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Charles River Laboratories International Inc (CRL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Charles River Laboratories International Inc (CRL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

What Charles River Laboratories (CRL)'s Morgan Stanley Upgrade Means For Shareholders - simplywall.st

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories International Inc (CRL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories International Inc (CRL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories International Inc (CRL) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories International Inc (CRL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch

Jun 17, 2026
pulisher
Jun 17, 2026

Morgan Stanley Upgrades Charles River Laboratories (CRL) Amid Bi - GuruFocus

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $220.29, Implies 19% Upside - TradingView

Jun 17, 2026
pulisher
Jun 17, 2026

Charles River upgraded, IQVIA downgraded at Morgan Stanley - Seeking Alpha

Jun 17, 2026
pulisher
Jun 17, 2026

This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga

Jun 17, 2026

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
DGX DGX
$209.88
price up icon 1.76%
MTD MTD
$1,263.75
price up icon 1.64%
$176.55
price down icon 0.62%
IQV IQV
$191.14
price up icon 2.53%
WAT WAT
$374.41
price down icon 0.66%
$261.91
price up icon 0.45%
大文字化:     |  ボリューム (24 時間):